PUBLIC COMPANY
saveEncoded Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
- phase2A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
- —Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
🐶 Hiring Signal
News
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 23d ago
- Frazier adds $1.1B+ to small and mid-sized biotech fundFrazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…biospace · 23d ago
- Encoded raises $275M series F for Dravet syndrome gene therapyEncoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.biospace · 24d ago
- Encoded closes $275M Series F for Dravet syndrome drugEncoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor. The precision genetic medicine biotech said Wednesday that…endpoints · 24d ago
- GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturingNeuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up its internal manufacturing capabilities.fiercebiotech · 25d ago
- #ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndromeA gene therapy designed by Encoded Therapeutics reduced seizures by 76% in children with Dravet syndrome, a severe neurodevelopmental disorder. The remarkable reduction was observed only in three p…endpoints · 4mo ago
- STAT+: Drug meant to make gene therapy safer may also make it less effectiveEncoded Therapeutics gives a heads-up to other gene therapy company about the trade-offs with a drug meant to improve safety.stat · 4mo ago
comments(0)
5-min edit window · permanent after that